A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.

de Braud, Filippo; Machiels, Jean-Pascal H; Boggiani, Daniela; Rottey, Sylvie W H; Duca, Matteo; Laruelle, Marie; Salvagni, Stefania; Damian, Silvia; Lapeire, Lore D F; Tiseo, Marcello; Dermine, Alexandre; Ould-Kaci, Mahmoud; Braunger, Juergen; Rascher, Juliane; Fischer, Daniela; Hoefler, Josef; Mariani, Gabriella L; Cresta, Sara

de Braud, Filippo; Machiels, Jean-Pascal H; Boggiani, Daniela; Rottey, Sylvie W H; Duca, Matteo; Laruelle, Marie; Salvagni, Stefania; Damian, Silvia; Lapeire, Lore D F; Tiseo, Marcello; Dermine, Alexandre; Ould-Kaci, Mahmoud; Braunger, Juergen; Rascher, Juliane; Fischer, Daniela; Hoefler, Josef; Mariani, Gabriella L; Cresta, Sara.

Afiliação

de Braud F; Fondazione IRCCS Istituto Nazionale dei Tumori, Medical Oncology Department, University of Milan, via G. Venezian, 1, 20133 Milan, Italy.
Machiels JH; Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Avenue Hippocrate 10, 200 Woluwe-Saint-Lambert, 1200 Brussels, Belgium.
Boggiani D; Medical Oncology Unit, University Hospital of Parma, Via Antonio Gramsci 14, 43126 Parma, Italy.
Rottey SWH; Drug Research Unit Ghent, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium.
Duca M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian, 1, 20133 Milan, Italy.
Laruelle M; Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université catholique de Louvain, Avenue Hippocrate 10, 200 Woluwe-Saint-Lambert, 1200 Brussels, Belgium.
Salvagni S; Policlinico S. Orsola Malphigi, via Giuseppe Massarenti, 13, 40138 Bologna, Italy.
Damian S; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian, 1, 20133 Milan, Italy.
Lapeire LDF; Drug Research Unit Ghent, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium.
Tiseo M; Medical Oncology Unit, University Hospital of Parma, Via Antonio Gramsci 14, 43126 Parma, Italy.
Dermine A; Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université catholique de Louvain, Avenue Hippocrate 10, 200 Woluwe-Saint-Lambert, 1200 Brussels, Belgium.
Ould-Kaci M; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd, Ridgefield, CT 06877, USA.
Braunger J; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riß, Germany.
Rascher J; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riß, Germany.
Fischer D; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riß, Germany.
Hoefler J; Staburo GmbH, Aschauer Str. 26b, 81549 Munich, Germany, on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Mariani GL; Boehringer Ingelheim, via Giovanni Lorenzini, 8, 20139 Milan, Italy.
Cresta S; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian, 1, 20133 Milan, Italy.